ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The trial will be conducted across eight sites in Maharashtra
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The facility has the capacity to produce one crore doses per day
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
The company has to approach the DCGI for approval to commence the trials
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Subscribe To Our Newsletter & Stay Updated
